We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,583.50 | 1,582.50 | 1,583.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.22 | 65.15B |
Date | Subject | Author | Discuss |
---|---|---|---|
17/4/2024 15:38 | 3. The US Food & Drug administration has accepted for review the biologics licence application for GSK's MenABCWY vaccine candidate. The vaccine provides coverage against groups of bacteria known to cause meningitis and other forms of meningococcal disease such as meningococcemia. | tradermichael | |
17/4/2024 15:35 | 2. EAGLE-1 phase III data show potential for gepotidacin as a new oral treatment option for uncomplicated urogenital gonorrhoea (GC) amid growing resistance to existing treatments · Gepotidacin achieved a 92.6% microbiological success rate and was non-inferior to the leading combination treatment · EAGLE-1 is the third positive pivotal trial for gepotidacin, a potential first-in-class oral antibiotic as part of GSK's industry-leading infectious diseases portfolio · Results will be presented at European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global | tradermichael | |
17/4/2024 15:34 | wins73 - agree, especially with all these RNS: 1. New long-term data show Shingrix continues to provide high protection against shingles in adults aged 50 and over for more than a decade · End-of-trial data show 79.7% efficacy in participants aged 50 years and over, six to 11 years after vaccination · Vaccine efficacy remains high at 82.0% at year 11 after initial vaccination · No new safety concerns were identified during the follow-up period | tradermichael | |
17/4/2024 14:54 | Not quite sure why price GSK has fallen back so far | wins73 | |
17/4/2024 11:11 | You've jinxed it now! :/ | rikky72 | |
17/4/2024 08:45 | Topped up yesterday | zam1 | |
17/4/2024 08:20 | Looks like 1500 will be revisited. Thought those days were long gone | spoole5 | |
16/4/2024 16:06 | GSK's latest meningitis vaccine accepted for review by US regulator. The US Food & Drug administration has accepted for review the biologics licence application for GSK's MenABCWY vaccine candidate. The vaccine provides coverage against groups of bacteria known to cause meningitis and other forms of meningococcal disease such as meningococcemia. | tradermichael | |
12/4/2024 15:50 | Pound at three month low, great for FTS 100 dollars. Most companies are.Be nice to see pound below 1.20 to dollar. | montyhedge | |
11/4/2024 14:03 | IN @ 1625.75 ..... ;0) | tradermichael | |
11/4/2024 12:35 | Dividend payment reached my AJ Bell accounts this morning .... | tradermichael | |
10/4/2024 14:32 | The Government said that it had removed this recommendation hours before the guidelines were published.......... however, you are correct - a seriously misplaced drive - healthcare should never be compromised on environmental considerations and should never have entered the discussion. | tradermichael | |
10/4/2024 13:18 | what are the names of these people who say they should make fewer drugs,its always the same with these government statements of some spokesman who we are not told their name, its a hidden agenda it seems.. name them i say??? | lippy4 | |
10/4/2024 10:31 | gsk on the naughty list at the moment | supermarky | |
09/4/2024 14:35 | See how Delaware goes first ........ | tradermichael | |
09/4/2024 14:00 | Perhaps GSK should re home to the US along with a multitude of others. | patientcapital | |
09/4/2024 13:00 | Yes, totally nuts! Pharmaceuticals companies were told to make fewer drugs for the sake of the environment, in new draft guidelines for businesses in the Government’s latest net zero drive. The suggestion was among a vast array of proposals which Britain’s biggest businesses have been told to consider as they are ordered to publish lengthy reports every year to show how they plan to meet their net zero targets. The Government said that it had removed this recommendation hours before the guidelines were published.......... | alphorn | |
09/4/2024 12:45 | https://www.telegrap | supermarky | |
09/4/2024 08:12 | Barclays 08/04/2024 Equal-weight Target 1,725.00p Reiteration | tradermichael | |
06/4/2024 08:16 | Alternativatly a new tax year. Guesss what. it is Monday... Maybe even the good old us will help the share price out. | upomega | |
05/4/2024 10:45 | Need some good.news from.delaware to turn this around | alibizzle | |
05/4/2024 10:42 | Wrong date, wrong thread .... | tradermichael | |
05/4/2024 09:17 | https://www.londonst | blackhorse23 | |
05/4/2024 08:01 | Back to normal for this then | spoole5 | |
04/4/2024 16:44 | I've felt the market was pricing that in already to an extent. | patientcapital |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions